NPAT fell 73% but dividend rose 71%, lifting payout to 162% of profit

NPAT fell 73.2% to NZ$5.2m and PBT fell 34.6% to NZ$29.8m on revenue down 8.7% to NZ$565.4m, with EBITDA off 21.7% to NZ$53.7m. The gap between PBT and NPAT growth (38.6pp) is not explained by the effective tax rate, which moved only from 16.2% to 17.2%.

Operating cash flow rose 44.2% to NZ$64.7m, lifting OCF/EBITDA conversion to 120.5%, an unprecedented high against Annolyse's 4-period historical mean of 72.1% (range 55.6%–110.8%). The interim dividend per share was raised 71.4% to 6.0c, taking the payout-to-NPAT ratio to 162.2% versus a historical mean of 26.3%. Gross borrowings rose 59.7% to NZ$65.6m even as cash climbed to NZ$77.6m.

• The 120.5% conversion rate reflects a NZ$23.7m working-capital release: trade debtors fell 29.3% and inventories fell 30.7%, with debtor days at 16.5 (below the 17.0–25.8 historical range) and inventory days at 19.1 (lower edge of the historical range). This release is the mirror image of lower volumes attributed to Cyclone Gabrielle, not a step-change in collections discipline. When volumes normalise, working capital will need to be rebuilt, reversing the tailwind.

• Dividend lift sits awkwardly against earnings. Raising the per-share dividend 71.4% while NPAT fell 73.2% pushed payout to 162.2% of NPAT — unprecedented in the supplied history. FCF pre-lease of NZ$47.9m (within the historical range) still covers the cash outlay at 17.7% of FCF, but the optics signal management is willing to look through the operating downturn rather than rebase distributions.

• Operating profitability has reset lower. EBITDA margin of 9.5% sits below the 11.1%–18.9% historical range, PBT margin of 5.3% is half the 10.6% mean, and ROE collapsed to 1.4% from 5.0%. Logistics revenue fell roughly 25%, shifting mix toward Global Proteins (52.8% of group revenue, up 1.1pp). The cleaner operating read is PBT down 34.6%, not the headline NPAT decline.

The release notes underlying EBITDA of NZ$67.5m (down 13%) was at the top end of FY23 guidance, and that Cyclone Gabrielle effects are expected to be largely confined to the 2023 season. Higher in-market prices partly offset volume losses.

The HY23 disclosure shows first-half NPAT of NZ$3.9m and a NZ$23.9m operating cash outflow, meaning the second half delivered NZ$1.3m NPAT but NZ$88.6m of operating inflow — a heavily back-half-skewed cash profile that confirms the conversion tailwind sits in the working-capital cycle rather than in second-half earnings momentum.

Pre-lease FCF of NZ$47.9m sits 11.6% above the 4-period mean of NZ$42.9m despite EBITDA falling 21.7%, which is only possible because the working-capital release contributed NZ$23.7m. Underlying capex of NZ$16.8m (3.0% of revenue, up 15.2%) suggests reinvestment is continuing through the cyclical trough, but FCF/NPAT of 914.9% is a ratio that will not repeat once trade debtors and inventories rebuild.

The balance sheet softened despite the cash beat. Net cash narrowed to NZ$12.0m from NZ$24.7m as gross borrowings rose NZ$24.5m, partly funding the higher dividend and the capex step-up. Total equity fell 1.8% to NZ$384.9m. None of this is alarming in isolation, but it means the durable read is weaker margins, a more leveraged capital structure, and a payout policy that is now disconnected from current-year earnings.

This briefing cannot assess management's quantitative FY24 outlook because no numerical guidance is supplied in the release materials.